To Find the Best Dose of pVGI.1(VEGF2) to Benefit Angina Patients When Given With
an Experimental Injection Catheter
Basic Study Information
Purpose:Location: University of Rochester
The purpose of this study is to determine the optimum effective dose of recombinant
DNA [pVGI.1(VEGF2)] gene therapy administered using an experimental cardiac direct
catheter (Stiletto™) system needed to benefit patients with severe Angina Pectoris.
Study Contact Information
Additional Study Details
Thank you for contacting us. People like you are helping URMC make our community and
world a healthier place. We sincerely appreciate your effort. A member of our research
team will be in touch with you.
Trial Not Found
The study you are looking for is not active at this time.
Return to Search